4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
MedKoo(授权代理)
主营:主营:抗癌化学试剂和激酶抑制剂
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > peptide > MedKoo/KX1-004featured/100mg/406540
商品详细MedKoo/KX1-004featured/100mg/406540
MedKoo/KX1-004featured/100mg/406540
MedKoo/KX1-004featured/100mg/406540
商品编号: 406540
品牌: MedKoo
市场价: ¥15000.00
美元价: 9000.00
产地: 美国(厂家直采)
公司:
产品分类: 多肽合成
公司分类: peptide
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

KX1-004
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:406540

CAS#:518058-84-9

Description:KX1-004 is an Src-protein tyrosine kinase inhibitor to reduce cisplatin ototoxicity while preserving its antitumor effect. KX1-004 has been used to protect the cochlea from hazardous noise.

Price and Availability

SizePriceShipping out timeQuantity
100mgUSD 7502 Weeks
200mgUSD 12502 Weeks
500mgUSD 19502 Weeks
1gUSD 29502 Weeks
2gUSD 39502 Weeks
5gUSD 59502 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

KX1-004, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406540Name: KX1-004CAS#: 518058-84-9Chemical Formula: C16H13FN2O2Exact Mass: 284.09611Molecular Weight: 284.29Elemental Analysis: C, 67.60; H, 4.61; F, 6.68; N, 9.85; O, 11.26

Synonym:KX1004; KX 1004; KX1-004.

IUPAC/Chemical Name:5-fluoro-N-(3-hydroxybenzyl)-1H-indole-2-carboxamide.

InChi Key:TUIHIKXCMCXXJG-UHFFFAOYSA-N

InChi Code:InChI=1S/C16H13FN2O2/c17-12-4-5-14-11(7-12)8-15(19-14)16(21)18-9-10-2-1-3-13(20)6-10/h1-8,19-20H,9H2,(H,18,21)

SMILES Code:O=C(C(N1)=CC2=C1C=CC(F)=C2)NCC3=CC=CC(O)=C3

Technical Data

Appearance:
white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

References

1: Fetoni AR, Bielefeld EC, Paludetti G, Nicotera T,Henderson D. A putative role of p53 pathway against impulse noiseinduced damage as demonstrated by protection with pifithrin-alpha and aSrc inhibitor. Neurosci Res. 2014 Apr-May;81-82:30-7. doi:10.1016/j.neures.2014.01.006. Epub 2014 Jan 25. PubMed PMID: 24472721.

2: Bielefeld EC, Tanaka C, Chen GD, Coling D, Li M, Henderson D, FetoniAR. An Src-protein tyrosine kinase inhibitor to reduce cisplatinototoxicity while preserving its antitumor effect. Anticancer Drugs.2013 Jan;24(1):43-51. doi: 10.1097/CAD.0b013e32835739fd. PubMed PMID:22828384.

3: Bielefeld EC, Hangauer D, Henderson D. Protection from impulsenoise-induced hearing loss with novel Src-protein tyrosine kinaseinhibitors. Neurosci Res. 2011 Dec;71(4):348-54. doi:10.1016/j.neures.2011.07.1836. Epub 2011 Aug 5. PubMed PMID: 21840347;PubMed Central PMCID: PMC3210387.

4: Bielefeld EC, Wantuck R, Henderson D. Postexposure treatment with aSrc-PTK inhibitor in combination with N-l-acetyl cysteine to reducenoise-induced hearing loss. Noise Health. 2011 Jul-Aug;13(53):292-8. doi:10.4103/1463-1741.82962. PubMed PMID: 21768733.

5: Bielefeld EC, Hynes S, Pryznosch D, Liu J, Coleman JK, Henderson D. Acomparison of the protective effects of systemic administration of apro-glutathione drug and a Src-PTK inhibitor against noise-inducedhearing loss. Noise Health. 2005 Oct-Dec;7(29):24-30. PubMed PMID:17478966.

6: Harris KC, Hu B, Hangauer D, Henderson D. Prevention of noise-inducedhearing loss with Src-PTK inhibitors. Hear Res. 2005 Oct;208(1-2):14-25.Epub 2005 Jun 13. PubMed PMID: 15950415.

品牌介绍
MedKoo 美帝药库公司以药物化学合成技术为核心,密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向,不断推出抗癌化合物新品种。 。 美帝药库MedKoo将在中国建立药物化学合成生产基地和多个现代化药物化合物存储仓库。 美帝药库的药物化合物来源于以下几个渠道:自主合成、委托化学合成、合作伙伴、和从国内外市场上选购。 MedKoo美帝药库的抗癌分子库 MedKoo的目标是打造全球规模最大、品种最多、类别最全和质量最好的小分子抗癌化合物库。MedKoo的抗癌药库将由下列5个分子库组成: (1)上市抗癌药库:该库将含有大约100个全球已批准上市的小分子抗癌化合物; (2)抗癌候选药物库:该分子库含有大约400个世界各国正在临床研究中抗癌小分子候选药物; (3)同系抗癌分子库:该分子库将含有多个化学结构类似或抗癌机制类似的分子包; (4)抗癌分子预制模块库:该库主要含有用于组建抗癌目标分子的分子模块包; (5)同位素标记抗癌分子库。